Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-25T11:32:10.650Z Has data issue: false hasContentIssue false

AGESMind clinical trial: SocialMIND® results at 16 weeks

Published online by Cambridge University Press:  19 July 2023

M. P. Vidal-Villegas*
Affiliation:
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Department of Psychiatry, Autonomous University of Madrid (UAM)
A. Abad Pérez
Affiliation:
Department of Psychiatry, Autonomous University of Madrid (UAM)
P. Herrero Ortega
Affiliation:
Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital
A. Oliva Lozano
Affiliation:
Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital
J. Garde González
Affiliation:
Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital
J. Andreo-Jover
Affiliation:
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Department of Psychiatry, Autonomous University of Madrid (UAM)
A. Muñoz-Sanjosé
Affiliation:
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Department of Psychiatry, Autonomous University of Madrid (UAM) Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital
R. Mediavilla
Affiliation:
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Department of Psychiatry, Autonomous University of Madrid (UAM) Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
B. Rodríguez-Vega
Affiliation:
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Department of Psychiatry, Autonomous University of Madrid (UAM) Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital
G. Lahera
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) Principe de Asturias University Hospital, University of Alcala de Henares, Madrid, Spain
Á. Palao-Tarrero
Affiliation:
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Department of Psychiatry, Autonomous University of Madrid (UAM) Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital
C. Bayón-Pérez
Affiliation:
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Department of Psychiatry, Autonomous University of Madrid (UAM) Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital
M. F. Bravo-Ortiz
Affiliation:
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Department of Psychiatry, Autonomous University of Madrid (UAM) Department of Psychiatry, Clinical Psychology and Mental Health, La Paz University Hospital Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Early intervention on a first psychotic episode is fundamental for a more favorable prognosis, and it usually combines pharmacological treatment, which mainly affects positive psychotic symptoms, with interventions that can improve the rest of the symptoms and associated problems such as deterioration in social functioning (Harvey & Penn, 2010; Fusar-Poli, McGorry & Kane, 2017). While Mindfulness is gaining more and more prominence in the field of psychotherapy (Chan et al., 2019; Cillesen et al., 2019), social cognition and social functioning are being researched as key targets on which to intervene after a first psychotic episode (Green, Horan & Lee, 2015).

SocialMIND® is a mindfulness-based social cognition training tailor-made to improve social functioning in people who have suffered a first psychotic episode within the last five years. It is currently being compared with a group Psychoeducational Multicomponent Intervention (PMI) in a Randomized Controlled Trial (RCT) (Mediavilla et al., 2019). Both group psychotherapies include 17 sessions delivered over a 9 month period: 8 weekly sessions, 4 biweekly sessions and 5 monthly sessions.

The results of SocialMIND® at 8 weeks showed improvements in social cognition and social functioning, specifically on affective social cognition and self-care (Mediavilla et al., 2021).

Objectives

To evaluate the efficacy of SocialMIND® in improving social functioning, measured by the Personal and Social Functioning (PSP) scale 16 weeks after starting the intervention, in people who have suffered a first psychotic episode in the last 5 years.

Methods

Randomized, controlled pilot trial (use of a psychoeducational multicomponent intervention or PMI as active comparator) of two parallel groups (SocialMIND® and PMI) with a 1:1 ratio using a blind evaluator.

Results

No statistically significant differences were found in the social functioning variable between the two treatment arms. Intragroup differences are observed in other secondary variables studied (social cognition) 16 weeks after starting the interventions.

Conclusions

SocialMIND® has not been shown to be more effective than a PMI in improving social functioning at 16 weeks after starting the intervention in people who have suffered a first psychotic episode in the five years prior to being included in the study.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.